pH sensitive fluorescent polydiacetylene liposome and delivery vehicle comprising same

US9675712B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9675712-B2
Application numberUS-201314418341-A
CountryUS
Kind codeB2
Filing dateJul 2, 2013
Priority dateJul 4, 2012
Publication dateJun 13, 2017
Grant dateJun 13, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to a drug delivery vehicle comprising a polydiacetylene liposome, wherein a lipid bilayer is formed by a mixture of 10,12-pentacosadiynoic acid (PCDA), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and N-palmitoyl homocysteine (PHC), and a drug to be delivered is encapsulated in an isolated inner space of a polydiacetylene liposome. The PDA liposome drug delivery vehicle of the present invention comprises a lipid layer formed by mixing different phospholipids, excluding polydiacetylene, so as to be stable, and thus any leakage problems of an encapsulated drug are eliminated. In addition, since the liposome is sensitive to a pH, the shape and size thereof can be readily changed through the formation of a liposome-liposome conjugate by the improved sensitivity of the drug delivery vehicle under a specific acidic requirement, thereby enabling selective drug release, and thus can be applied as a drug delivery vehicle for various target materials. Additionally, the release of a drug can be controlled by controlling a pH requirement of the surroundings, and a drug release process can be monitored in real time through the fluorescence expressed by the stimulation to the surroundings.

First claim

Opening claim text (preview).

What is claimed is: 1. A polydiacetylene liposome having an inner space isolated from a medium by a lipid layer membrane, wherein the lipid layer comprises 10,12-pentacosadiynoic acid (PCDA), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and N-palmitoyl homocysteine (PHC), wherein a molar ratio of the PCDA, DOPE and PHC is 6:3:1. 2. The polydiacetylene liposome of claim 1 , wherein the polydiacetylene liposome increases in diameter with decreasing pH. 3. The polydiacetylene liposome of claim 1 , wherein the polydiacetylene liposome fluoresces inherently in response to an environmental stimulus comprising a change in pH, to produce a real-time monitorable fluorescence. 4. A drug delivery vehicle comprising a polydiacetylene liposome having an inner space isolated from a medium by a lipid layer membrane, wherein the lipid layer comprises 10,12-pentacosadiynoic acid (PCDA), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and N-palmitoyl homocysteine (PHC), and the drug to be delivered is encapsulated in the isolated inner space of the polydiacetylene liposome, wherein a molar ratio of the PCDA, DOPE and PHC is 6:3:1. 5. The drug delivery vehicle of claim 4 , wherein the liposome increases in diameter with decreasing pH. 6. The drug delivery vehicle of claim 5 , wherein the drug in the liposome is released when the polydiacetylene liposome is fused with the adjacent polydiacetylene liposome, and during the drug release, the polydiacetylene liposome itself fluoresces inherently by environmental stimulus, and the fluorescence can be monitored in real -time. 7. The drug delivery vehicle of claim 4 , wherein the drug is an anti-biotic drug or an anti-cancer drug. 8. A drug delivery method using the drug delivery vehicle of claim 4 , wherein the drug delivery vehicle controls a drug release time and a drug release amount by the following steps: (a) controlling the drug release time by controlling pH of the medium within a range of pH 3 to pH 7 with respect to the drug delivery vehicle; (b) expressing inherent fluorescence of the liposome according to a pH change which is an external stimulus while releasing the drug by controlling the drug release time at same time; and (c) confirming and monitoring the drug release and the drug release amount in real-time by measuring the fluorescence intensity of the liposome.

Assignees

Inventors

Classifications

  • Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911}) · CPC title

  • comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543}) · CPC title

  • liposome, i.e. bilayered vesicular structure · CPC title

  • Amino acids, e.g. glycine, EDTA or aspartame · CPC title

  • characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9675712B2 cover?
The present invention relates to a drug delivery vehicle comprising a polydiacetylene liposome, wherein a lipid bilayer is formed by a mixture of 10,12-pentacosadiynoic acid (PCDA), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and N-palmitoyl homocysteine (PHC), and a drug to be delivered is encapsulated in an isolated inner space of a polydiacetylene liposome. The PDA liposome drug de…
Who is the assignee on this patent?
Univ Korea Res & Bus Found
What technology area does this patent fall under?
Primary CPC classification A61K49/0084. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).